Abstract: A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135-45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g. In an embodiment, the device is used as a point-of-care and/or portable device. Further, the present disclosure describes software that, when executed by a processor, causes the device to perform the disclosed functions.

Abstract: A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135-45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g. In an embodiment, the device is used as a point-of-care and/or portable device. Further, the present disclosure describes software that, when executed by a processor, causes the device to perform the disclosed functions.

Abstract: The present invention provides a regulatory T (Treg) cell expressing an antigen chimeric receptor (CAR) comprising a) at least one antigen binding domain, b) a transmembrane domain, and c) a cytoplasmic signaling domain comprising at least one primary cytoplasmic signaling domain and at least the co-stimulatory signaling domain of CD137, wherein said antigen binding domain specifically binds an antigen that is expressed on the surface of a target cell or a tag of a tagged polypeptide that binds to an antigen expressed on the surface of a target cell or a soluble antigen. Compositions comprising said Treg cells, and methods of enrichment and analysis of activated Tregs that express said CAR are also disclosed.

Abstract: The present invention provides a method polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a flexible matrix, wherein said matrix is of polymeric material; and b) attached to said polymeric flexible matrix one or more polyclonal stimulatory agents which provide activation signals to the T cells; thereby activating and inducing the T cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices. If the stimulatory agents are attached to separate beads, fine-tuning of nanomatrices for the stimulation of the T cells is possible.

Abstract: The invention relates to a cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135?45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g.

Abstract: A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135?45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g. In an embodiment, the device is used as a point-of-care and/or portable device. Further, the present disclosure describes software that, when executed by a processor, causes the device to perform the disclosed functions.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: The invention relates to a cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135?45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: The present invention provides a method for polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains, and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide activation signals to the T cells; thereby activating and inducing the T cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate mobile matrices. If the stimulatory agents are attached to separate nanomatrices, fine-tuning of nanomatrices for the stimulation of the T cells is possible. Closed cell culture systems also benefit from this method.

Abstract: The present invention provides an in-vitro method for inducing proliferation of NK cells, the method comprising contacting a population of NK cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains; and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide activation signals to the NK cells; thereby activating and inducing the NK cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices. If the stimulatory agents are attached to separate beads, fine-tuning of nanomatrices for the proliferation of the NK cells is possible. Closed cell culture systems also benefit from this method.

Abstract: The invention relates to a method for identifying T-cell stimulating protein fragments using the following steps: a) detecting the amino acid sequence of an antigen; b) subdividing the found amino acid sequence of the antigen into protein fragments; c) synthesizing at least one protein fragment; d) incubating a suspension containing t-cells with the protein fragments; e) identifying an induced T-cell cytokine or activation marker by flow-through cytometry, and; f) assigning the T-cells, with which T-cell cytokines and/or activation markers were identified, to the protein fragments which were incubated with the T-cells. The corresponding protein fragments/peptides are synthetically produced with the assistance of the detected positive sequence, and said corresponding protein fragments/peptides can be utilized to produce a medicament for immunostimulation.

Abstract: The invention relates to a cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135-45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g.

Abstract: The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells.

Abstract: The present invention provides a method polyclonal stimulation of T cells, the method comprising contacting a population of T cells with a nanomatrix, the nanomatrix comprising a) a flexible matrix, wherein said matrix is of polymeric material; and b) attached to said polymeric flexible matrix one or more polyclonal stimulatory agents which provide activation signals to the T cells; thereby activating and inducing the T cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices. If the stimulatory agents are attached to separate beads, fine-tuning of nanomatrices for the stimulation of the T cells is possible.

Abstract: The invention relates to a method for sensitive quantitative and/or qualitative analysis of target T cells comprising the steps a) enrichment of said cells from a mixture of said cells and other cells in a sample by the use of one or more activation markers expressed on antigen-activated T cells in a parallel cell sorting process and b) analysis of the cells of step a). The invention relates also to a method of diagnosing diseases based on the analysis of the target T cells.

Abstract: The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates to the use of modulating the immune response, primarily in case of infection reactions. The invention in particular relates to the use for treating illnesses associated with infections. The invention further relates to the use for reducing IL-22 production in T-cells.

Abstract: The invention relates to a method for modulating the inflammatory potential of T cells, in particular by regulating the IL-10 production in pro-inflammatory T cells, by influencing the activity or activation of the Notch and STAT4 signaling pathways. The invention also relates to the use of the method for inhibiting inflammations or in immunosuppression. More specifically, the invention relates to the use of the method in the treatment of diseases associated with inflammations. Furthermore, the invention relates to the use of the method for reducing the IL-10 production in pro-inflammatory T cells and thus the enhancement of T cell-mediated immune reaction, especially in the event of infections, tumor diseases or vaccinations against infections or tumors.

Abstract: The Use of particles with signal-emitting characteristics and at least one group with an affinity for labeled nucleic acids for the detection of labeled nucleic acids which are hybridized with nucleic acids immobilized on a surface. Another subject matter of the invention are supports with particles with signal-emitting characteristics and at least one group with an affinity for labeled nucleic acids for the detection of labeled nucleic acids.